{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:00:59Z","timestamp":1784228459387,"version":"3.55.0"},"reference-count":110,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100003399","name":"Basic Research Project from Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["17JC1402200"],"award-info":[{"award-number":["17JC1402200"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91859105"],"award-info":[{"award-number":["91859105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8196112802"],"award-info":[{"award-number":["8196112802"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2020,9,18]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>The majority of patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced\nstage that can only benefit from systemic treatments. Although HCC is highly treatmentresistant,\nsignificant achievements have been made in the molecular targeted therapy and immunotherapy\nof HCC. In addition to regorafenib, cabozantinib and ramucirumab were approved for the second-\nline targeted treatment by the FDA after disease progression on sorafenib. Nivolumab failed to\ndemonstrate remarkable benefit in overall survival (OS) as first-line therapy, while pembrolizumab\ndid not achieve pre-specified statistical significance in both OS and progression-free survival (PFS) as\nsecond-line treatment. Combinations of targeted agents, immune checkpoint inhibitors and other interventions\nshowed favorable results. In this review, we summarized the progress of systemic therapy\nin HCC and discussed the future directions of the treatment of HCC.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566523220666200628014530","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T06:18:28Z","timestamp":1593497908000},"page":"84-99","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes"],"prefix":"10.2174","volume":"20","author":[{"given":"Chen-Hao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Pei","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University and Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"Bray F.","year":"2018","unstructured":"Bray F.; Ferlay J.; Soerjomataram I.; Siegel R.L.; Torre L.A.; Jemal A.; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018,68(6),394-424","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"Villanueva A.","year":"2019","unstructured":"Villanueva A.; Hepatocellular Carcinoma. N Engl J Med 2019,380(15),1450-1462","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"Zehir A.","year":"2017","unstructured":"Zehir A.; Benayed R.; Shah R.H.; Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017,23(6),703-713","journal-title":"Nat Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","volume":"169","year":"2017","unstructured":"Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell Cancer Genome Atlas Research Network2017,169(7),1327-1341","journal-title":"Cell"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.cell.2019.08.052","volume":"179","author":"Gao Q.","year":"2019","unstructured":"Gao Q.; Zhu H.; Dong L.; Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell 2019,179(2),561-577.e22","journal-title":"Cell"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-019-0987-8","volume":"567","author":"Jiang Y.","year":"2019","unstructured":"Jiang Y.; Sun A.; Zhao Y.; Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature 2019,567(7747),257-261","journal-title":"Nature"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-019-0794-6","volume":"12","author":"Zhu X-D.","year":"2019","unstructured":"Zhu X-D.; Sun H-C.; Emerging agents and regimens for hepatocellular carcinoma. J Hematol Oncol 2019,12(1),110","journal-title":"J Hematol Oncol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"Cheng A-L.","year":"2009","unstructured":"Cheng A-L.; Kang Y-K.; Chen Z.; Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009,10(1),25-34","journal-title":"Lancet Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/1078-0432.CCR-18-0847","volume":"25","author":"Goyal L.","year":"2019","unstructured":"Goyal L.; Zheng H.; Abrams T.A.; A Phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2019,25(1),80-89","journal-title":"Clin Cancer Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41416-019-0443-4","volume":"120","author":"Assenat E.","year":"2019","unstructured":"Assenat E.; Pageaux G-P.; Th\u00e9zenas S.; Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. Br J Cancer 2019,120(9),896-902","journal-title":"Br J Cancer"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1200\/JCO.2019.37.4_suppl.365","volume":"37","author":"Yau T.C.","year":"2019","unstructured":"Yau T.C.; Tang V.; Leung R.C-Y.; Randomized phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2019,37(Suppl. 4),365","journal-title":"J Clin Oncol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jamaoncol.2019.2792","volume":"5","author":"Abou-Alfa G.K.","year":"2019","unstructured":"Abou-Alfa G.K.; Shi Q.; Knox J.J.; Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol 2019,5(11),1582-1588","journal-title":"JAMA Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S2468-1253(19)30040-8","volume":"4","author":"Merle P.","year":"2019","unstructured":"Merle P.; Blanc J-F.; Phelip J-M.; Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol RELIVE Investigators2019,4(6),454-465","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1186\/s12885-019-6198-8","volume":"19","author":"Kondo M.","year":"2019","unstructured":"Kondo M.; Morimoto M.; Kobayashi S.; Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. BMC Cancer 2019,19(1),954","journal-title":"BMC Cancer"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"He M.","year":"2019","unstructured":"He M.; Li Q.; Zou R.; Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol 2019,5(7),953-960","journal-title":"JAMA Oncol"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","volume":"69","author":"Kudo M.","year":"2019","unstructured":"Kudo M.; Ueshima K.; Ikeda M.; Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2019,69(8),1492-1501","journal-title":"Gut"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","volume":"70","author":"Park J-W.","year":"2019","unstructured":"Park J-W.; Kim Y.J.; Kim D.Y.; Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. J Hepatol 2019,70(4),684-691","journal-title":"J Hepatol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/DDDT.S191334","volume":"13","author":"Huang C-C.","year":"2019","unstructured":"Huang C-C.; Chen H-Y.; Chang R-H.; A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015. Drug Des Devel Ther 2019,13,397-404","journal-title":"Drug Des Devel Ther"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2019.04.021","volume":"71","author":"Jouve J-L.","year":"2019","unstructured":"Jouve J-L.; Lecomte T.; Bouch\u00e9 O.; PRODIGE-11 investigators\/collaborators. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. J Hepatol 2019,71(3),516-522","journal-title":"J Hepatol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","volume":"52","author":"Ikeda K.","year":"2017","unstructured":"Ikeda K.; Kudo M.; Kawazoe S.; Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol 2017,52(4),512-519","journal-title":"J Gastroenterol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"Kudo M.","year":"2018","unstructured":"Kudo M.; Finn R.S.; Qin S.; Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018,391(10126),1163-1173","journal-title":"Lancet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","volume":"55","author":"Yamashita T.","year":"2020","unstructured":"Yamashita T.; Kudo M.; Ikeda K.; REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol 2020,55(1),113-122","journal-title":"J Gastroenterol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.2019.37.4_suppl.186","volume":"37","author":"Kudo M.","year":"2019","unstructured":"Kudo M.; Finn R.S.; Qin S.; Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT). J Clin Oncol 2019,37(Suppl. 4),186","journal-title":"J Clin Oncol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1159\/000503032","volume":"8","author":"Kudo M.","year":"2019","unstructured":"Kudo M.; Ueshima K.; Chiba Y.; Objective response by mrecist is an independent prognostic factor for overall survival in hepatocellular carcinoma treated with sorafenib in the SILIUS trial. Liver Cancer 2019,8(6),505-519","journal-title":"Liver Cancer"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s00535-019-01554-0","volume":"54","author":"Kobayashi M.","year":"2019","unstructured":"Kobayashi M.; Kudo M.; Izumi N.; Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol 2019,54(6),558-570","journal-title":"J Gastroenterol"},{"key":"ref=26","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0501","author":"Kim JJ","unstructured":"Kim JJ; McFarlane T; Tully S;  Lenvatinib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma: a cost-utility analysis Oncologist 2019; 0501","journal-title":"Lenvatinib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma: a cost-utility analysis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"Bruix J.","year":"2017","unstructured":"Bruix J.; Qin S.; Merle P.; Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017,389(10064),56-66","journal-title":"Lancet"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10637-018-0707-5","volume":"37","author":"Yoo C.","year":"2019","unstructured":"Yoo C.; Park J-W.; Kim Y.J.; Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. Invest New Drugs 2019,37(3),567-572","journal-title":"Invest New Drugs"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s10637-019-00801-8","volume":"38","author":"Ogasawara S.","year":"2020","unstructured":"Ogasawara S.; Ooka Y.; Itokawa N.; Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Invest New Drugs 2020,38(1),172-180","journal-title":"Invest New Drugs"},{"key":"ref=30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010036","volume":"12","author":"Facciorusso A.","year":"2019","unstructured":"Facciorusso A.; Abd El Aziz M.A.; Sacco R.; Efficacy of regorafenib in hepatocellular carcinoma patients: A systematic review and meta-analysis. Cancers (Basel) 2019,12(1)","journal-title":"Cancers (Basel)"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/annonc\/mdz247.081","volume":"30","author":"Bruix J.","year":"2019","unstructured":"Bruix J.; Reig M.; Merle P.; Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial. Ann Oncol 2019,30,291","journal-title":"Ann Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1053\/j.gastro.2019.01.261","volume":"156","author":"Teufel M.","year":"2019","unstructured":"Teufel M.; Seidel H.; K\u00f6chert K.; Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology 2019,156(6),1731-1741","journal-title":"Gastroenterology"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"Abou-Alfa G.K.","year":"2018","unstructured":"Abou-Alfa G.K.; Meyer T.; Cheng A-L.; Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018,379(1),54-63","journal-title":"N Engl J Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1200\/JCO.2019.37.15_suppl.4088","volume":"37","author":"Abou-Alfa G.K.","year":"2019","unstructured":"Abou-Alfa G.K.; Meyer T.; Cheng A-L.; Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial. J Clin Oncol 2019,37(Suppl. 15),4088","journal-title":"J Clin Oncol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"v257","DOI":"10.1093\/annonc\/mdz247.006","volume":"30","author":"Rimassa L.","year":"2019","unstructured":"Rimassa L.; Kelley R.K.; Meyer T.; Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019,30,v257-v258","journal-title":"Ann Oncol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1111\/liv.14257","volume":"39","author":"Liao W.","year":"2019","unstructured":"Liao W.; Huang J.; Hutton D.; Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma. Liver Int 2019,39(12),2408-2416","journal-title":"Liver Int"},{"key":"ref=37","doi-asserted-by":"publisher","DOI":"10.1177\/1756284819878304","volume":"12,","author":"Shlomai A.","year":"2019","unstructured":"Shlomai A.; Leshno M.; Goldstein D.A.; Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis. Therap Adv Gastroenterol 2019,12,","journal-title":"Therap Adv Gastroenterol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.6004\/jnccn.2018.7275","volume":"17","author":"Soto-Perez-de-Celis E.","year":"2019","unstructured":"Soto-Perez-de-Celis E.; Aguiar P.N.; Cord\u00f3n M.L.; Chavarri-Guerra Y.; Lopes G.L.; Cost-effectiveness of cabozantinib in the second-line treatment of advanced hepatocellular carcinoma. J Natl Compr Canc Netw 2019,17(6),669-675","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S2468-1253(17)30290-X","volume":"3","author":"Kudo M.","year":"2018","unstructured":"Kudo M.; Cheng A-L.; Park J-W.; Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol 2018,3(1),37-46","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12032-019-1272-2","volume":"36","author":"Hidaka H.","year":"2019","unstructured":"Hidaka H.; Izumi N.; Aramaki T.; Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). Med Oncol 2019,36(6),52","journal-title":"Med Oncol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"Shen G.","year":"2018","unstructured":"Shen G.; Zheng F.; Ren D.; Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 2018,11(1),120","journal-title":"J Hematol Oncol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"v288","DOI":"10.1093\/annonc\/mdz247.077","volume":"30","author":"Zhou A.","year":"2019","unstructured":"Zhou A.; Sun Y.; Zhang W.; Anlotinib for advanced hepatocellular carcinoma: Interim results from the phase II ALTER0802 study. Ann Oncol 2019,30,v288-v289","journal-title":"Ann Oncol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/jco.2014.32.15_suppl.4019","volume":"32","author":"Qin S.","year":"2014","unstructured":"Qin S.; Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial. J Clin Oncol 2014,32(Suppl. 15),4019-4020","journal-title":"J Clin Oncol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/15384047.2018.1529099","volume":"20","author":"Yang Z.","year":"2019","unstructured":"Yang Z.; Chen G.; Cui Y.; The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study. Cancer Biol Ther 2019,20(3),321-327","journal-title":"Cancer Biol Ther"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1038\/s41467-019-12606-7","volume":"10","author":"Wei L.","year":"2019","unstructured":"Wei L.; Lee D.; Law C-T.; Genome-wide CRISPR\/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat Commun 2019,10(1),4681","journal-title":"Nat Commun"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"El-Khoueiry A.B.","year":"2017","unstructured":"El-Khoueiry A.B.; Sangro B.; Yau T.; Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 2017,389(10088),2492-2502","journal-title":"Lancet"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"v874","DOI":"10.1093\/annonc\/mdz394.029","volume":"30","author":"Yau T.","year":"2019","unstructured":"Yau T.; Park J.; Finn R.; CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019,30,v874-v875","journal-title":"Ann Oncol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"Wolchok J.D.","year":"2013","unstructured":"Wolchok J.D.; Kluger H.; Callahan M.K.; Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013,369(2),122-133","journal-title":"N Engl J Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"Hellmann M.D.","year":"2018","unstructured":"Hellmann M.D.; Ciuleanu T-E.; Pluzanski A.; Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018,378(22),2093-2104","journal-title":"N Engl J Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","volume":"35","author":"Hammers H.J.","year":"2017","unstructured":"Hammers H.J.; Plimack E.R.; Infante J.R.; Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The CheckMate 016 study. J Clin Oncol 2017,35(34),3851-3858","journal-title":"J Clin Oncol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1200\/JCO.2020.38.4_suppl.512","volume":"38","author":"He A.R.","year":"2020","unstructured":"He A.R.; Yau T.; Hsu C.; Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. J Clin Oncol 2020,38(Suppl. 4),512","journal-title":"J Clin Oncol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-19-1090","volume":"25","author":"Doi T.","year":"2019","unstructured":"Doi T.; Muro K.; Ishii H.; A phase I study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors. Clin Cancer Res 2019,25(22),6614-6622","journal-title":"Clin Cancer Res"},{"key":"ref=53","doi-asserted-by":"publisher","author":"Kudo M","unstructured":"Kudo M; Ikeda M; Motomura K; A phase Ib study of lenvatinib\n (LEN) plus nivolumab (NIV) in patients (pts) with unresectable\n hepatocellular carcinoma (uHCC): Study 117. J Clin Oncol\n 2020; 38(4_suppl): 513.","DOI":"10.1200\/JCO.2020.38.4_suppl.513"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"Zhu A.X.","year":"2018","unstructured":"Zhu A.X.; Finn R.S.; Edeline J.; Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol KEYNOTE-224 investigators2018,19(7),940-952","journal-title":"Lancet Oncol"},{"key":"ref=55","unstructured":"National Comprehensive Cancer Network"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"Finn R.S.","year":"2020","unstructured":"Finn R.S.; Ryoo B-Y.; Merle P.; Pembrolizumab As second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial. J Clin Oncol 2020,38(3),193-202","journal-title":"J Clin Oncol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"Qin S.","year":"2020","unstructured":"Qin S.; Ren Z.; Meng Z.; Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020,21(4),571-580","journal-title":"Lancet Oncol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","volume":"25","author":"Xu J.","year":"2019","unstructured":"Xu J.; Zhang Y.; Jia R.; Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res 2019,25(2),515-523","journal-title":"Clin Cancer Res"},{"key":"ref=59","doi-asserted-by":"publisher","author":"Floudas CS","unstructured":"Floudas CS; Xie C; Brar G; Combined immune checkpoint\ninhibition (ICI) with tremelimumab and durvalumab in patients\n with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas\n (BTC). J Clin Oncol 2019; 37(4_suppl): 336.","DOI":"10.1200\/JCO.2019.37.4_suppl.336"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","volume":"15","author":"Gao Q.","year":"2009","unstructured":"Gao Q.; Wang X-Y.; Qiu S-J.; Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009,15(3),971-979","journal-title":"Clin Cancer Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"Gong J.","year":"2018","unstructured":"Gong J.; Chehrazi-Raffle A.; Reddi S.; Salgia R.; Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 2018,6(1),8","journal-title":"J Immunother Cancer"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/annonc\/mdz446.002","volume":"30","author":"Cheng A-L.","year":"2019","unstructured":"Cheng A-L.; Qin S.; Ikeda M.; IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo)+ bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann Oncol 2019,30,186-187","journal-title":"Ann Oncol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","volume":"19","author":"Barlesi F.","year":"2018","unstructured":"Barlesi F.; Vansteenkiste J.; Spigel D.; Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol 2018,19(11),1468-1479","journal-title":"Lancet Oncol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11523-018-0571-4","volume":"13","author":"Shirley M.","year":"2018","unstructured":"Shirley M.; Avelumab: A review in metastatic merkel cell carcinoma. Target Oncol 2018,13(3),409-416","journal-title":"Target Oncol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1200\/JCO.2019.37.15_suppl.4072","volume":"37","author":"Kudo M.","year":"2019","unstructured":"Kudo M.; Motomura K.; Wada Y.; First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100). J Clin Oncol 2019,37(15)(Suppl.),4072","journal-title":"J Clin Oncol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2217\/imt-2018-0110","volume":"11","author":"Zhang N.","year":"2019","unstructured":"Zhang N.; Tu J.; Wang X.; Chu Q.; Programmed cell death-1\/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. Immunotherapy 2019,11(5),429-441","journal-title":"Immunotherapy"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1111\/cas.13811","volume":"109","author":"Li S.","year":"2018","unstructured":"Li S.; Han X.; Lyu N.; Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma. Cancer Sci 2018,109(12),3726-3736","journal-title":"Cancer Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","volume":"25","author":"Wang J.","year":"2019","unstructured":"Wang J.; Sun J.; Liu L.N.; Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med 2019,25(4),656-666","journal-title":"Nat Med"},{"key":"ref=69","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1615817","volume":"8","author":"Moehler M.","year":"2019","unstructured":"Moehler M.; Heo J.; Lee H.C.; Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). OncoImmunology 2019,8(8)","journal-title":"OncoImmunology"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"Fuchs C.S.","year":"2014","unstructured":"Fuchs C.S.; Tomasek J.; Yong C.J.; Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet REGARD Trial Investigators2014,383(9911),31-39","journal-title":"Lancet"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"Garon E.B.","year":"2014","unstructured":"Garon E.B.; Ciuleanu T-E.; Arrieta O.; Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014,384(9944),665-673","journal-title":"Lancet"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"Zhu A.X.","year":"2019","unstructured":"Zhu A.X.; Kang Y-K.; Yen C-J.; Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol REACH-2 study investigators2019,20(2),282-296","journal-title":"Lancet Oncol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s40265-014-0302-9","volume":"74","author":"Keating G.M.","year":"2014","unstructured":"Keating G.M.; Bevacizumab: a review of its use in advanced cancer. Drugs 2014,74(16),1891-1925","journal-title":"Drugs"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","volume":"26","author":"Siegel A.B.","year":"2008","unstructured":"Siegel A.B.; Cohen E.I.; Ocean A.; Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008,26(18),2992-2998","journal-title":"J Clin Oncol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12885-019-5487-6","volume":"19","author":"He L.","year":"2019","unstructured":"He L.; Deng H.; Lei J.; Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies. BMC Cancer 2019,19(1),276","journal-title":"BMC Cancer"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"v875","DOI":"10.1093\/annonc\/mdz394.030","volume":"30","author":"Lee M.","year":"2019","unstructured":"Lee M.; Ryoo B-Y.; Hsu C-H.; Randomised efficacy and safety results for Atezolizumab (Atezo)+ bevacizumab (Bev) in patients (PTS) with previously untreated, unresectable hepatocellular carcinoma (HCC). Ann Oncol 2019,30,v875","journal-title":"Ann Oncol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"Hong D.S.","year":"2020","unstructured":"Hong D.S.; DuBois S.G.; Kummar S.; Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol 2020,21(4),531-540","journal-title":"Lancet Oncol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"Hoadley K.A.","year":"2018","unstructured":"Hoadley K.A.; Yau C.; Hinoue T.; Cancer genome atlas network. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 2018,173(2),291-304","journal-title":"Cell"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdy539","volume":"30","author":"Hong D.S.","year":"2019","unstructured":"Hong D.S.; Bauer T.M.; Lee J.J.; Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol 2019,30(2),325-331","journal-title":"Ann Oncol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"Doebele R.C.","year":"2020","unstructured":"Doebele R.C.; Drilon A.; Paz-Ares L.; Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020,21(2),271-282","journal-title":"Lancet Oncol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1002\/mc.22592","volume":"56","author":"Ungerleider N.","year":"2017","unstructured":"Ungerleider N.; Han C.; Zhang J.; Yao L.; Wu T.; TGF\u03b2 signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells. Mol Carcinog 2017,56(4),1302-1311","journal-title":"Mol Carcinog"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s10637-018-0636-3","volume":"37","author":"Ikeda M.","year":"2019","unstructured":"Ikeda M.; Morimoto M.; Tajimi M.; A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma. Invest New Drugs 2019,37(1),118-126","journal-title":"Invest New Drugs"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/liv.14113","volume":"39","author":"Faivre S.","year":"2019","unstructured":"Faivre S.; Santoro A.; Kelley R.K.; Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int 2019,39(8),1468-1477","journal-title":"Liver Int"},{"key":"ref=84","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000056","volume":"10","author":"Kelley R.K.","year":"2019","unstructured":"Kelley R.K.; Gane E.; Assenat E.; A phase 2 study of galunisertib (TGF-\u03b21 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma. Clin Transl Gastroenterol 2019,10(7)","journal-title":"Clin Transl Gastroenterol"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/cas.14254","volume":"111","author":"Bang Y-J.","year":"2020","unstructured":"Bang Y-J.; Su W-C.; Schuler M.; Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts. Cancer Sci 2020,111(2),536-547","journal-title":"Cancer Sci"},{"key":"ref=86","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919889001","volume":"11,","author":"Qin S.","year":"2019","unstructured":"Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol 2019,11,","journal-title":"Ther Adv Med Oncol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"Yu H.","year":"2014","unstructured":"Yu H.; Lee H.; Herrmann A.; Buettner R.; Jove R.; Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014,14(11),736-746","journal-title":"Nat Rev Cancer"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"607","DOI":"10.4143\/crt.2014.249","volume":"47","author":"Oh D-Y.","year":"2015","unstructured":"Oh D-Y.; Lee S-H.; Han S-W.; Phase I study of OPB-31121, an oral STAT3 inhibitor, in patients with advanced solid tumors. Cancer Res Treat 2015,47(4),607-615","journal-title":"Cancer Res Treat"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1111\/hepr.12504","volume":"45","author":"Okusaka T.","year":"2015","unstructured":"Okusaka T.; Ueno H.; Ikeda M.; Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma. Hepatol Res 2015,45(13),1283-1291","journal-title":"Hepatol Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"7408","DOI":"10.1074\/jbc.M009604200","volume":"276","author":"Christian S.","year":"2001","unstructured":"Christian S.; Ahorn H.; Koehler A.; Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem 2001,276(10),7408-7414","journal-title":"J Biol Chem"},{"key":"ref=91","first-page":"1733","volume":"40","author":"Leonardi G.C.","year":"2012","unstructured":"Leonardi G.C.; Candido S.; Cervello M.; The tumor microenvironment in hepatocellular carcinoma. (review) Int J Oncol 2012,40(6),1733-1747","journal-title":"Int J Oncol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s10637-018-0713-7","volume":"37","author":"Doi T.","year":"2019","unstructured":"Doi T.; Aramaki T.; Yasui H.; A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors. Invest New Drugs 2019,37(5),1061-1074","journal-title":"Invest New Drugs"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1634\/theoncologist.2018-0443","volume":"24","author":"Hahn A.W.","year":"2019","unstructured":"Hahn A.W.; Pal S.K.; Agarwal N.; Targeting endoglin to treat metastatic renal cell carcinoma: lessons from osler-weber-rendu syndrome. Oncologist 2019,24(2),143-145","journal-title":"Oncologist"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2019.37.4_suppl.268","volume":"37","author":"Raghav K.P.S.","year":"2019","unstructured":"Raghav K.P.S.; Lee R.T.; Paluri R.K.; An open-label phase Ib\/2 trial of TRC105 plus sorafenib in patients with advanced\/metastatic hepatocellular carcinoma (HCC) (NCT01806064). J Clin Oncol 2019,37(4)(Suppl.),268","journal-title":"J Clin Oncol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jhep.2016.04.004","volume":"65","author":"Abou-Alfa G.K.","year":"2016","unstructured":"Abou-Alfa G.K.; Puig O.; Daniele B.; Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol 2016,65(2),289-295","journal-title":"J Hepatol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1200\/JCO.2017.35.15_suppl.3049","volume":"35","author":"Zhai B.","year":"2017","unstructured":"Zhai B.; Shi D.; Gao H.; A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r\/r GPC3+ HCC). J Clin Oncol 2017,35(15)(Suppl.),3049","journal-title":"J Clin Oncol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1053\/j.gastro.2016.09.008","volume":"152","author":"Gao Q.","year":"2017","unstructured":"Gao Q.; Wang Z-C.; Duan M.; Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents. Gastroenterology 2017,152(1),232-242","journal-title":"Gastroenterology"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/cr.2018.11","volume":"28","author":"Duan M.","year":"2018","unstructured":"Duan M.; Hao J.; Cui S.; Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. Cell Res 2018,28(3),359-373","journal-title":"Cell Res"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2019.12.014","volume":"72","author":"Dong L.","year":"2020","unstructured":"Dong L.; Peng L.; Ma L.; Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. J Hepatol 2020,72(5),896-908","journal-title":"J Hepatol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/s12885-019-5760-8","volume":"19","author":"Eilard M.S.","year":"2019","unstructured":"Eilard M.S.; Andersson M.; Naredi P.; A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. BMC Cancer 2019,19(1),568","journal-title":"BMC Cancer"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fonc.2019.00019","volume":"9","author":"Rizell M.","year":"2019","unstructured":"Rizell M.; Sternby Eilard M.; Andersson M.; Andersson B.; Karlsson-Parra A.; Suenaert P.; Phase 1 trial with the cell-based immune primer ilixadencel, alone, and combined with sorafenib, in advanced hepatocellular carcinoma. Front Oncol 2019,9,19","journal-title":"Front Oncol"},{"key":"ref=102","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0718","author":"Labeur T.A.","year":"2019","unstructured":"Labeur T.A.; Achterbergh R.; Takkenberg B.; Van Delden O.; Math\u00f4t R.; Kl\u00fcmpen H.J.; Sorafenib for patients with hepatocellular carcinoma and child-pugh b liver cirrhosis: lessons learned from a terminated study. Oncologist 2019","journal-title":"Oncologist"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11523-019-00663-3","volume":"14","author":"Mokdad A.A.","year":"2019","unstructured":"Mokdad A.A.; Zhu H.; Beg M.S.; Efficacy and safety of bavituximab in combination with sorafenib in advanced hepatocellular carcinoma: a single-arm, open-label, Phase II clinical trial. Target Oncol 2019,14(5),541-550","journal-title":"Target Oncol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1002\/cncr.32206","volume":"125","author":"Kambhampati S.","year":"2019","unstructured":"Kambhampati S.; Bauer K.E.; Bracci P.M.; Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Cancer 2019,125(18),3234-3241","journal-title":"Cancer"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1002\/cncr.32339","volume":"125","author":"Feun L.G.","year":"2019","unstructured":"Feun L.G.; Li Y-Y.; Wu C.; Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer 2019,125(20),3603-3614","journal-title":"Cancer"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"v286","DOI":"10.1093\/annonc\/mdz247.073","volume":"30","author":"Llovet J.","year":"2019","unstructured":"Llovet J.; Shepard K.; Finn R.; A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results. Ann Oncol 2019,30,v286-v287","journal-title":"Ann Oncol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1002\/ijc.32317","volume":"145","author":"Weekes C.","year":"2019","unstructured":"Weekes C.; Lockhart A.C.; Lee J.J.; A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. Int J Cancer 2019,145(9),2450-2458","journal-title":"Int J Cancer"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"510","DOI":"10.4143\/crt.2018.226","volume":"51","author":"Yoo C.","year":"2019","unstructured":"Yoo C.; Kang J.; Lim H.Y.; Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma. Cancer Res Treat 2019,51(2),510-518","journal-title":"Cancer Res Treat"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00280-019-03924-0","volume":"84","author":"Yamazaki K.","year":"2019","unstructured":"Yamazaki K.; Doi T.; Ikeda M.; Phase I trial of pimasertib monotherapy in Japanese patients with solid tumors and those with hepatocellular carcinoma. Cancer Chemother Pharmacol 2019,84(5),1027-1037","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.2217\/fon-2019-0097","volume":"15","author":"Qin S.","year":"2019","unstructured":"Qin S.; Finn R.S.; Kudo M.; RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol 2019,15(16),1811-1822","journal-title":"Future Oncol"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/183210","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/183210\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/183210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T20:22:49Z","timestamp":1610482969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183210\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,9,18]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523220666200628014530","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}